Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.40 | N/A | +10.67% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.40 | N/A | +10.67% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism regarding the company's financial health. They highlighted the importance of maintaining a strong EPS as a positive indicator.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They emphasized a focus on long-term growth strategies.
Amgen's earnings report shows a positive surprise in EPS, which contributed to a slight increase in the stock price. The lack of revenue data and guidance may leave some investors cautious, but the EPS beat suggests the company is managing its costs effectively. The stock's modest gain reflects a generally favorable reception to the earnings news.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SLB Limited
Oct 21, 2011